Abstract:The exact pathogenesis of chronic obstructive pulmonary disease (COPD) remains largely unknown. While current management strategies are effective at stabilizing the disease or relief the symptoms, new approaches are required to target underlying disease process and reverse lung function deterioration. Recent research showed that pneumonia bacteria is critical in disease progression and gut microbiome is likely perturbed in COPD, which is usually accompanied by a decreased intestinal microbial diversity and a disturbance in immune system, contributing to a chronic inflammation. The cross-talk between gut microbes and lungs, termed as the “gut-lung axis,” is known to impact immune response and homeostasis in the airway. Although the gut and respiratory microbiota exhibit compositional differences, the gut and lung showed similarities in the origin of epithelia of both gastrointestinal and respiratory tracts, the anatomical structure, and early-life microbial colonization. Evidence showed that respiratory infection might be prevented, or at least dampened by regulating gut microbial ecosystem; thus, a promising yet understudied area of COPD management is nutrition-based preventive strategies. COPD patient is often deficient in nutrient such as antioxidant, vitamins, and fiber intake. However, further larger-scale randomized clinical trials (RCTs) are required to establish the role of these nutrition-based diet in COPD management. In this review, we highlight the important and complex interaction of microbiota and immune response on gut-lung axis. Further research into the modification and improvement of the gut microbiota and new interventions through diet, probiotics, vitamins, and fecal microbiota transplantation is extreme critical to provide new preventive therapies for COPD.

The role and mechanism of gut-lung axis mediated bidirectional communication in the occurrence and development of chronic obstructive pulmonary disease

The role of gut-lung axis in COPD: Pathogenesis, immune response, and prospective treatment

COPD and Gut–Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics

The Bidirectional Gut-Lung Axis in COPD.

Imbalance of gut microbiota is involved in the development of chronic obstructive pulmonary disease: A review

A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases

Lung microbiome, gut–lung axis and chronic obstructive pulmonary disease

Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease

Gut–lung Microbiota Interactions in Chronic Obstructive Pulmonary Disease (COPD): Potential Mechanisms Driving Progression to COPD and Epidemiological Data

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

The association between the respiratory tract microbiome and clinical outcomes in patients with COPD

Interactions between the lung microbiome and host immunity in chronic obstructive pulmonary disease

Gut-Lung Microbiota in Chronic Pulmonary Diseases: Evolution, Pathogenesis, and Therapeutics

Gut Microbiota Modulation in the Management of Chronic Obstructive Pulmonary Disease: A Literature Review

The lung-gut crosstalk in respiratory and inflammatory bowel disease

Gut microbiota: A new insight into lung diseases

The Intriguing Connection Between the Gut and Lung Microbiomes

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment

Lung microbiota: implications and interactions in chronic pulmonary diseases

Chronic obstructive pulmonary disease and the airway microbiome: A review for clinicians

The Gut-Liver-Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease.